# Immuno Cure

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/immuno-cure

- Industry: Biotechnology
- Headquarters: Sha Tin, Hong Kong SAR - China
- Website: www.immunocure.hk
- Total disclosed funding: $12M
- Latest round: Series A (Jul 27, 2023)
- Investors on record: 1

## About

Established in 2022 and based in Beijing, China, Immuno Cure operates as a biotechnology group that provides DNA vaccine platform and Anti-?42PD1 antibody drug platform. The company is headquartered in Hong Kong and has branches in Beijing, Shanghai and Shenzhen.. In September 2020, it acquired a majority stake in Shanghai Taruisha Healthy Technology Co.,Ltd. In June 2023, the company initiated clinical phase IIa trial in Hong Kong.  In July 2023, it raised USD 12 million in series A funding led by Gobi Partners. Xia Jin, the CEO and co-founder of the company, once served as the distinguished fellow of the Chinese Academy of Sciences and executive director of the Vaccine Center at the Shanghai Pasteur Institute. The company has many strategic partners, such as Teresa, Opus Capital and The University of Hong Kong Shenzhen Hospital.

The company develops DNA vaccine platform and Anti-?42PD1 antibody drug platform. DNA vaccine platform can inhibit viruses and tumor cells. Anti-?42PD1 antibody drug platform can reduce inflammatory response. Its R&D pipeline includes IMC-001, IMC-002 and IMC-003.

## Funding rounds

- Series A, Jul 27, 2023, $12M — Gobi Partners

## Investors

- Gobi Partners (https://capitalatlas.ai/funds/gobi-partners) — Series A